Omada Health (NASDAQ:OMDA) CFO Sells $381,332.05 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CFO Steven Cook sold 15,235 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $25.03, for a total value of $381,332.05. Following the completion of the sale, the chief financial officer owned 187,209 shares in the company, valued at $4,685,841.27. This trade represents a 7.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Omada Health Trading Down 1.4%

Shares of OMDA stock opened at $24.04 on Friday. Omada Health, Inc. has a 1-year low of $10.28 and a 1-year high of $26.92. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of 480.80 and a beta of 1.73. The stock has a 50-day moving average of $20.99 and a 200-day moving average of $16.49.

Omada Health (NASDAQ:OMDA) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.10. The company had revenue of $87.83 million for the quarter, compared to analyst estimates of $80.93 million. Omada Health had a return on equity of 2.60% and a net margin of 1.39%. Sell-side analysts forecast that Omada Health, Inc. will post -0.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

OMDA has been the topic of a number of recent analyst reports. Evercore restated an “outperform” rating and issued a $20.00 price target on shares of Omada Health in a research report on Friday, May 8th. Robert W. Baird increased their price objective on shares of Omada Health from $15.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday. Citigroup reissued an “outperform” rating on shares of Omada Health in a research note on Friday. Citizens Jmp boosted their target price on shares of Omada Health from $27.00 to $32.00 and gave the company a “market outperform” rating in a report on Friday. Finally, Barclays upped their price target on shares of Omada Health from $20.00 to $25.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $26.50.

Hedge Funds Weigh In On Omada Health

Several institutional investors have recently added to or reduced their stakes in OMDA. Hsbc Holdings PLC bought a new position in shares of Omada Health during the 2nd quarter worth approximately $435,000. Canada Pension Plan Investment Board bought a new stake in shares of Omada Health in the 2nd quarter valued at $281,000. Legal & General Group Plc acquired a new position in shares of Omada Health during the 2nd quarter valued at $76,000. The Manufacturers Life Insurance Company acquired a new position in shares of Omada Health during the 2nd quarter valued at $215,000. Finally, Bank of Nova Scotia bought a new position in Omada Health during the second quarter worth $617,000.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.